AIC 649

Drug Profile

AIC 649

Alternative Names: AIC649

Latest Information Update: 25 Jan 2016

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer AiCuris
  • Class Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 05 Jan 2016 Phase-I clinical trials in Hepatitis B (Combination therapy, First-line therapy) in Germany (IM)
  • 05 Jan 2016 Preclinical trials in Hepatitis B in Germany (IM) before January 2016
  • 05 Jan 2016 Pharmacodynamics data from preclinical studies in Hepatitis B released by AiCuris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top